Accelerating vaccine development

Traditional vaccine development is slow by design with extensive scientific review, rigorous preclinical testing, and at least three phases of progressive clinical trials. Historically, it takes between five and 10 years and over $1 billion to develop a vaccine and to make sure it's safe and effective. And that's before making enough vaccine for everyone and administering it to patients around the world.

So how do vaccines work? And how do we speed up the process?

When a virus like SARS-CoV-2 enters your body, your immune system responds by producing specific antibodies to both neutralize the current infection
and watch out for that virus's characteristic pattern, should it ever reappear. 

Traditional vaccines use all or part of killed or weakened virus to teach your immune system to recognize and act on those specific characteristics without the virus ever entering the body. Because these vaccines start as live pathogen they require extensive biosafety facilities and significant time and cost to develop.

New vaccines are taking a different approach.

Using advanced sequencing technologies, scientists are able to obtain and analyze the genetic code of a new virus within hours of discovering it. After isolating the code for the virus's specific recognizable proteins, scientists can create a template for that protein, a short, single stranded sequence of nucleotides called messenger RNA. If the mRNA sequence can be delivered to enough cells, they will create the viral proteins right within the cell, giving your immune system the means to recognize and fight any virus with these characteristics.

RNA vaccines can be made in large quantities in a matter of days at relatively low cost. However, they expire quickly and must be stored at extremely low temperatures, making distribution difficult.

Despite these challenges and the need for more testing, RNA and other novel vaccine methods have the potential to significantly accelerate vaccine development, and by refining the process for preclinical testing and clinical trials, we will soon be much more agile in the fight against an infectious disease.

Genomic surveillance: Tracking the evolution of a pandemic

JAX is contributing to the COVID-19 genomic surveillance effort, which will be a key component of bringing the pandemic under control.

Read more

COVID-19 and its aftermath in children

Connecticut Children’s is partnering with The Jackson Laboratory for virus testing and research into a post-viral immune syndrome.

Read more

Protecting West Hartford's first responders

Rapid COVID-19 testing at The Jackson Laboratory for Genomic Medicine is keeping West Hartford fire, rescue, and EMT teams healthy so they can safely help others.

Read more

Protecting seniors during the pandemic

Coordinated COVID-19 testing at a Connecticut long-term care complex aims to prevent infection among the elderly and staff.

Read more

Perspective: On the front lines of COVID-19 testing

Rachel Goldfeder is a JAX computational scientist who has taken on the role of project manager for the JAX COVID-19 CLIA Lab testing team.

Read more

JAX donors contribute $100,000 to new COVID-19 models

A generous gift from Jackson Laboratory (JAX) donors will support the development of new humanized mouse models for beating COVID-19, the infectious disease caused by the novel coronavirus that has infected over 7 million worldwide, killing over 400,000 people.

Read more

Want to hear the latest from JAX? Subscribe to our newsletters!

Thanks for reading articles from JAX!

Subscribe to our newsletters for the latest news!